Lineage Cell Therapeutics

@LineageCell

A clinical-stage biotechnology company developing novel cell therapies for unmet medical needs.

NYSE American and TASE: LCTX
Vrijeme pridruživanja: kolovoz 2012.

Tweetovi

Blokirali ste korisnika/cu @LineageCell

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @LineageCell

  1. 30. sij

    Lineage is developing a novel to treat dry age-related macular degeneration (), the leading cause of irreversible vision loss in the US. OpRegen is currently in Phase I/IIa and has the potential to help many patients.

    Poništi
  2. 28. sij

    What is OPC1? OPC1 is an oligodendrocyte progenitor for the treatment of acute spinal cord injuries (), partially funded through our partnership with . Learn more about this therapy:

    Poništi
  3. 27. sij

    Learn about the competitive landscape in this week's Lineage where CEO Brian Culley discusses how OpRegen is positioned in contrast to our competitors

    Poništi
  4. 24. sij

    The overall safety profile of OPC1 has remained excellent with robust motor recovery in upper extremities maintained through Year 2 SCiStar Study patient follow-ups available Learn more about our cell therapy development:

    Poništi
  5. 23. sij

    Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cellular therapies to treat unmet medical needs. Learn more about the innovative in our pipeline:

    Poništi
  6. 21. sij

    Top industry execs including CFO Brandi Roberts came together to discuss "where is headed" with of

    Poništi
  7. 16. sij

    CEO Brian Culley chatted with Proactive’s Christine Corrado in San Francisco

    Poništi
  8. 16. sij

    On the OPC1 Phase 1/2a trial, principal investigator Dr. Donald Leslie commented: “If OPC1 could deliver even modest improvements in motor or sensory function, it would result in significant improvements in quality of life for people with SCI.”

    Poništi
  9. 14. sij

    Great lunch today with CEO Brian Culley and other industry execs discussing the cutting edge in with of

    Poništi
  10. proslijedio/la je Tweet
    13. sij

    At , they are developing to fight macular degeneration, spinal cord injuries and cancer. talks to of at .

    Poništi
  11. 13. sij
    Poništi
  12. 13. sij

    "Lineage's vision restoration cell therapy is a one-two punch. One technology with two product candidates and different methods of action. Stopping degenerative disease for early stage and restoring visual function for late state ." -Francois Binette at

    Poništi
  13. 13. sij

    "Our goal with the Vision Restoration Program is to develop transformational cell therapies that will have a great impact on the relatively unaddressed blinding retinal diseases to restore visual function." -Francois Binette, Global Head of R&D at

    Poništi
  14. 13. sij

    We are at today with Global Head of R&D at , Francois Binette, presenting an update on our Vision Restoration Program.

    Poništi
  15. 13. sij

    CEO Brian shares for patients with , spinal cord injuries, and cancer! Data from multiple programs are expected to read out this year.

    Poništi
  16. 10. sij

    A look into our future shows us pursuing opportunities to obtain development support for our programs through external partnerships.

    Poništi
  17. 9. sij

    Be in the know! Watch this week’s Lineage with CEO Brian Culley discussing the clinical development of and the research partnership with .

    Poništi
  18. 9. sij

    We look forward to collecting additional data on OpRegen and completing enrollment of our Phase I/IIa study for in Q1 2020. Learn more about our trial here:

    Poništi
  19. 8. sij

    Lineage continues to provide updates to the SCiStar Study, which so far has an excellent safety profile and robust motor recovery maintained. Learn more about the study results here:

    Poništi
  20. 7. sij

    Lineage is looking forward to ! Our executive team will be reviewing the clinical programs and 2020 plans.

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·